FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2404127287> ?p ?o ?g. }

• W2404127287 abstract "There is now significant evidence emerging from the pivotal trials of AIs versus Tamoxifen (AIOG) demonstrating the value of meta-analysis of key clinical questions. The Trans-AIOG group has been tasked with the exploration of key molecular/biomarker questions that are pertinent to meta-analyses of biomarkers (past/present/future) in AIOG trials. HER2 has been long proposed as a marker of endocrine resistance. Data from three trials, before the era of HER-directed therapy, suggest a potential role for HER2 to select patients for treatment with AIs. However the individual trials lack power to test treatment-by-HER2 interaction due to sample size and low HER2+ve rates. A meta-analysis of the predictive value of HER2 status, specifically within the first 3 years of endocrine therapy, has the potential to inform patient selection for or strategies with AIs. The pre-existing standardization of methodology for HER2 (IHC/FISH) facilitates analysis of existing data from BIG-1-98, TEAM and ATAC for this key marker. Analysis plan: Following a prospectively-designed analysis plan, patient-level data from 3 randomized phase III trials (ATAC, BIG 1-98, TEAM) comparing AIs to tamoxifen during the first 2-3 years of adjuvant treatment were collected at the CRCTU (Birmingham UK), accounting for both the established time-dependency of relapse in HER2+ve, anti-endocrine treated patients and to address the clinical question of upfront vs sequential strategies for AIs. For each trial, covariate-adjusted Cox models estimated HER2-by-treatment (AI vs Tam) interaction on distant recurrence-free interval-censored at 2-2.75 years follow-up. A meta-analysis of the HER2-by-treatment interaction terms and of treatment effects according to HER2 status was performed. Results: 12129 patients with centrally-confirmed ER and HER2 status, 1092 (9%) HER2+ve, with 473 (4%; 111 among HER2+ve) distant recurrences were analyzed. The meta-analysis estimated a pooled HER2-by-treatment interaction of 1.61 (95% CI 1.01,2.57), reflecting treatment effect hazard ratio(AI/Tam) of HR=1.13 (0.75,1.71) among HER2+ve and HR=0.70 (0.56,0.87) among HER2-ve. There was heterogeneity among interaction terms (I-squared=59%, p=.09) that resulted from treatment effect heterogeneity among HER2+ve subgroup (I2=71%, p=.03), not the HER2-ve subgroup (I2=0%). The results for disease-free survival were similar. Conclusion: An individual patient data meta-analysis across 3 trials (ATAC, BIG 1-98, TEAM) conducted prior to standard use of HER2-directed adjuvant therapy demonstrated a marginally-significant interaction between HER2 status and treatment with AIs vs Tamoxifen in the 2-2.75 years prior to potential switching between Tamoxifen and AIs. Patients with HER2-ve cancers experienced improved outcomes when treated with AIs vs Tamoxifen whilst patients with HER+ve cancers fared no better, or slightly worse, during AI treatment. However, the small number of HER2+ve cancers and events even in this meta-analysis may explain a large degree of heterogeneity in the treatment effects within the HER2+ve subgroups across the 3 trials. Other causes, perhaps related to subtle differences between AIs, cannot be excluded. Citation Format: Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell9Orto P, Thurlimann BJK, Seynaeve C, Putter H, Brookes CL, Forbes JF, Colleoni MA, Bayani J, van de Velde CJH, Viale G, Cuzick J, Dowsett M, Rea DW, On Behalf of the Translational Aromatase Inhibitor Overview Group (Trans-AIOG). HER2 status as predictive marker for AI vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr S4-06." @default.
• W2404127287 created "2016-06-24" @default.
• W2404127287 creator A5013882207 @default.
• W2404127287 creator A5018134073 @default.
• W2404127287 creator A5018625601 @default.
• W2404127287 creator A5019863052 @default.
• W2404127287 creator A5020297035 @default.
• W2404127287 creator A5031357461 @default.
• W2404127287 creator A5052841786 @default.
• W2404127287 creator A5056490185 @default.
• W2404127287 creator A5057689412 @default.
• W2404127287 creator A5058767202 @default.
• W2404127287 creator A5062106369 @default.
• W2404127287 creator A5065594377 @default.
• W2404127287 creator A5073613763 @default.
• W2404127287 creator A5073637560 @default.
• W2404127287 creator A5080138909 @default.
• W2404127287 creator A5081370568 @default.
• W2404127287 creator A5085892864 @default.
• W2404127287 creator A5089973122 @default.
• W2404127287 date "2016-02-15" @default.
• W2404127287 modified "2023-09-26" @default.
• W2404127287 title "Abstract S4-06: HER2 status as predictive marker for AI vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2" @default.
• W2404127287 doi "https://doi.org/10.1158/1538-7445.sabcs15-s4-06" @default.
• W2404127287 hasPublicationYear "2016" @default.
• W2404127287 type Work @default.
• W2404127287 sameAs 2404127287 @default.
• W2404127287 citedByCount "0" @default.
• W2404127287 crossrefType "proceedings-article" @default.
• W2404127287 hasAuthorship W2404127287A5013882207 @default.
• W2404127287 hasAuthorship W2404127287A5018134073 @default.
• W2404127287 hasAuthorship W2404127287A5018625601 @default.
• W2404127287 hasAuthorship W2404127287A5019863052 @default.
• W2404127287 hasAuthorship W2404127287A5020297035 @default.
• W2404127287 hasAuthorship W2404127287A5031357461 @default.
• W2404127287 hasAuthorship W2404127287A5052841786 @default.
• W2404127287 hasAuthorship W2404127287A5056490185 @default.
• W2404127287 hasAuthorship W2404127287A5057689412 @default.
• W2404127287 hasAuthorship W2404127287A5058767202 @default.
• W2404127287 hasAuthorship W2404127287A5062106369 @default.
• W2404127287 hasAuthorship W2404127287A5065594377 @default.
• W2404127287 hasAuthorship W2404127287A5073613763 @default.
• W2404127287 hasAuthorship W2404127287A5073637560 @default.
• W2404127287 hasAuthorship W2404127287A5080138909 @default.
• W2404127287 hasAuthorship W2404127287A5081370568 @default.
• W2404127287 hasAuthorship W2404127287A5085892864 @default.
• W2404127287 hasAuthorship W2404127287A5089973122 @default.
• W2404127287 hasConcept C121608353 @default.
• W2404127287 hasConcept C126322002 @default.
• W2404127287 hasConcept C143998085 @default.
• W2404127287 hasConcept C185592680 @default.
• W2404127287 hasConcept C2777176818 @default.
• W2404127287 hasConcept C2781197716 @default.
• W2404127287 hasConcept C530470458 @default.
• W2404127287 hasConcept C535046627 @default.
• W2404127287 hasConcept C55493867 @default.
• W2404127287 hasConcept C71924100 @default.
• W2404127287 hasConcept C95190672 @default.
• W2404127287 hasConceptScore W2404127287C121608353 @default.
• W2404127287 hasConceptScore W2404127287C126322002 @default.
• W2404127287 hasConceptScore W2404127287C143998085 @default.
• W2404127287 hasConceptScore W2404127287C185592680 @default.
• W2404127287 hasConceptScore W2404127287C2777176818 @default.
• W2404127287 hasConceptScore W2404127287C2781197716 @default.
• W2404127287 hasConceptScore W2404127287C530470458 @default.
• W2404127287 hasConceptScore W2404127287C535046627 @default.
• W2404127287 hasConceptScore W2404127287C55493867 @default.
• W2404127287 hasConceptScore W2404127287C71924100 @default.
• W2404127287 hasConceptScore W2404127287C95190672 @default.
• W2404127287 hasLocation W24041272871 @default.
• W2404127287 hasOpenAccess W2404127287 @default.
• W2404127287 hasPrimaryLocation W24041272871 @default.
• W2404127287 hasRelatedWork W1535320194 @default.
• W2404127287 hasRelatedWork W2018696748 @default.
• W2404127287 hasRelatedWork W2123379359 @default.
• W2404127287 hasRelatedWork W2124414372 @default.
• W2404127287 hasRelatedWork W2404845386 @default.
• W2404127287 hasRelatedWork W2405407273 @default.
• W2404127287 hasRelatedWork W2406458692 @default.
• W2404127287 hasRelatedWork W2592827583 @default.
• W2404127287 hasRelatedWork W2595594315 @default.
• W2404127287 hasRelatedWork W2706669954 @default.
• W2404127287 hasRelatedWork W2790250024 @default.
• W2404127287 hasRelatedWork W2792624742 @default.
• W2404127287 hasRelatedWork W2793113004 @default.
• W2404127287 hasRelatedWork W2914761223 @default.
• W2404127287 hasRelatedWork W2918221101 @default.
• W2404127287 hasRelatedWork W3006557651 @default.
• W2404127287 hasRelatedWork W3009418596 @default.
• W2404127287 hasRelatedWork W3009807523 @default.
• W2404127287 hasRelatedWork W3129805563 @default.
• W2404127287 hasRelatedWork W3172138849 @default.
• W2404127287 isParatext "false" @default.
• W2404127287 isRetracted "false" @default.
• W2404127287 magId "2404127287" @default.
• W2404127287 workType "article" @default.